CHM

12.5%

1.8¢ chimeric therapeutics limited

CLTX-CAR T is a game changer, page-11

First 11 Last

Share
Profile

Follow
stockrock

5,487 Posts.

8940

02/03/21

15:11

Post #: 51455473
Share

Originally posted by Zenox: ↑

This portion of the prospectus appears to imply that the intention is for CHM to essentially be commercial arm for CTLX CAR T cell therapies, whether in its current form or following any and all modifications made to this technology. It's fascinating stuff to see how City of Hope (Beckman Institute) are looking to apply this technology, with CHM looking to sublease should clinical trials be successful.

(a) defining the scope of tumours potentially amenable to CLTX-CAR T cell therapy;

This covers the current use of the technology

(b) investigating the pairing of CLTX-CAR T cell therapy with other Glioblastoma therapeutic strategies;

Exploring effectiveness of the current technology as a combination therapy.

(c) exploring the enhancement of the activity of the present CLTX-CAR construct;

For example, to either modify the current CLTX construct to enhance specificity to other types of cancers or to optimise through modifying non-targeting domains as mentioned here: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500824/

(d) developing dual-targeting CARs incorporating CLTX;

To make a significant modification to the current construct to make it into hybrid construct of sorts.

(e) investigating other potential broadly-acting CAR targeting strategies for solid tumours; and

To incorporate a new construct?

(f) exploring other research areas, such as generating different immune cell products or assessing the ability to generate allogeneic CLTX-CAR T products

As described.

And to achieve these developments, CHM have to:

All of this makes a 90 mill market cap look cheap.

Expand

glad you were able to point that out, and yes with M&A activity at heightened levels for CAR-T therapies, even at phase I trials... and FDA approvals with small sized (50-80 patients) phase II trials... this is IMO a very lucrative market to be in at the moment... getting a foot in the door when a field of medicine is in the midst of rapid growth and progress is something I find to be a very attractive opportunity... not without risk of course

CHM Price at posting: 32.5¢ Sentiment: Buy Disclosure: Held
10 Upvote

1 Great analysis

Reply

Top Stories

NEU

Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress

Emerald & Azure score Digger & Dealer awards

Dale Gillham's weekly wrap: picking resilient stocks in a volatile global market

Bitcoin: Current State of Play & Where to Next | Swyftx

TKM

Trek Metals jumps 5% as gold & REE drill run kicks off at Christmas Creek in the Kimberley

Revolutionary inverter technology leads the clean energy charge

TNC

True North increases silver metal at QLD's Vero deposit by 20%

HZR

Hazer Group reports ten days of continuous operation at graphite-manufacturing test facility

From the Floor with Federal Opposition Leader Peter Dutton at Diggers & Dealers 2024

Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling

There are more pages in this discussion • 73 more messages in this thread...

First 11 Last

Add CHM (ASX) to my watchlist

(20min delay)
Last 1.8¢		Change 0.002(12.5%)		Mkt cap ! $15.96M

Open	High	Low	Value	Volume
1.7¢	2.0¢	1.7¢	$28.92K	1.577M

Buyers (Bids)

No.	Vol.	Price($)
1	95523	1.8¢

Sellers (Offers)

Price($)	Vol.	No.
1.9¢	2523	1

View Market Depth

No.	Vol.	Price($)
3	490039	0.017
10	1253317	0.016
10	1735472	0.015
3	2575142	0.014
2	266900	0.013

Price($)	Vol.	No.
0.020	584413	9
0.021	420857	2
0.022	1423767	5
0.023	200000	2
0.024	400000	3

Last trade - 16.10pm 09/08/2024 (20 minute delay)

CHM (ASX) Chart

CLTX-CAR T is a game changer, page-11

Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress

Emerald & Azure score Digger & Dealer awards

Dale Gillham's weekly wrap: picking resilient stocks in a volatile global market

Bitcoin: Current State of Play & Where to Next | Swyftx

Trek Metals jumps 5% as gold & REE drill run kicks off at Christmas Creek in the Kimberley

Revolutionary inverter technology leads the clean energy charge

True North increases silver metal at QLD's Vero deposit by 20%

Hazer Group reports ten days of continuous operation at graphite-manufacturing test facility

From the Floor with Federal Opposition Leader Peter Dutton at Diggers & Dealers 2024

Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

CLTX-CAR T is a game changer, page-11

Top Stories

Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress

Emerald & Azure score Digger & Dealer awards

Dale Gillham's weekly wrap: picking resilient stocks in a volatile global market

Bitcoin: Current State of Play & Where to Next | Swyftx

Trek Metals jumps 5% as gold & REE drill run kicks off at Christmas Creek in the Kimberley

Revolutionary inverter technology leads the clean energy charge

True North increases silver metal at QLD's Vero deposit by 20%

Hazer Group reports ten days of continuous operation at graphite-manufacturing test facility

From the Floor with Federal Opposition Leader Peter Dutton at Diggers & Dealers 2024

Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News